1. Home
  2. RPRX vs GFS Comparison

RPRX vs GFS Comparison

Compare RPRX & GFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royalty Pharma plc

RPRX

Royalty Pharma plc

HOLD

Current Price

$45.16

Market Cap

19.4B

Sector

Health Care

ML Signal

HOLD

Logo GlobalFoundries Inc.

GFS

GlobalFoundries Inc.

HOLD

Current Price

$46.33

Market Cap

22.9B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
RPRX
GFS
Founded
1996
2009
Country
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
19.4B
22.9B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RPRX
GFS
Price
$45.16
$46.33
Analyst Decision
Strong Buy
Buy
Analyst Count
4
12
Target Price
$47.75
$45.08
AVG Volume (30 Days)
4.2M
4.2M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
2.09%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$39.10
$6.71
Revenue Next Year
$5.02
$8.85
P/E Ratio
$25.25
$30.16
Revenue Growth
N/A
N/A
52 Week Low
$29.66
$29.77
52 Week High
$46.14
$50.98

Technical Indicators

Market Signals
Indicator
RPRX
GFS
Relative Strength Index (RSI) 73.30 57.37
Support Level $42.50 $41.38
Resistance Level $46.14 $50.98
Average True Range (ATR) 1.00 2.38
MACD 0.19 0.31
Stochastic Oscillator 82.91 60.59

Price Performance

Historical Comparison
RPRX
GFS

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

About GFS GlobalFoundries Inc.

GlobalFoundries is a top-five contract semiconductor manufacturer globally. It was originally the manufacturing arm of Advanced Micro Devices before it was spun out in 2009. The foundry sells chips into a range of end markets including smartphones, PCs, Internet of Things, data centers, automotive, industrial, and so on, but primarily focuses on more mature process technologies. Until 2021, the firm was privately held by Mubadala Investment, the sovereign wealth fund of the United Arab Emirates, which remains its controlling shareholder today. GlobalFoundries merged with Chartered Semiconductor Manufacturing in 2009 and acquired IBM's chipmaking business in 2015. GF is headquartered in Malta, New York, and employs about 13,000 people.

Share on Social Networks: